The **Illumina** stock has **dropped 77%** and further fell **6.8% in the past week**. Several analysts maintain a positive outlook on the company as a **long-term value buy**. Recently, Illumina has addressed **developments in China** where imports of their gene sequencing products were banned due to Trump's tariffs. Activist investor **Keith Meister joined Illumina's board** to provide greater value for shareholders, while **Dr. Scott Gottlieb was elected Chair** of the board. Despite an **EPS estimate of $4.50 for FY25**, the company has been described as a **'challenged company' by Jim Cramer**. In terms of **product innovations**, Illumina has introduced new technologies for **multiomic research and spatial transcriptomics**. It also launched **a pilot proteomics program in partnership with the UK Biobank**. Illumina's **financial performance has been below expectations** with Q4 earnings missing estimates, prompting a lowering of the company's outlook and plans to **cut $100m in costs**. Nonetheless, major indices have recognized Illumina for sustainability efforts and as a top player in the genomics age.
Illumina ILMN News Analytics from Tue, 09 Jul 2024 07:00:00 GMT to Thu, 10 Apr 2025 20:49:08 GMT -
Rating -7
- Innovation 5
- Information 7
- Rumor -6
